ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Bioinformatics approach to identifying molecular targets of Danlou tablet against atherosclerosis: a machine learning pharmacology study.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This research aims to identify novel molecular targets and generate mechanistic hypotheses for Danlou Tablet (DLT) in the treatment of atherosclerosis (AS) using an integrative computational framework combining network pharmacology, bioinformatics, single-cell RNA sequencing (scRNA-seq), machine learning, molecular docking, molecular dynamics simulation, and preliminary target engagement validation. Bioactive components and targets of DLT were retrieved from the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP). AS-associated targets were extracted from OMIM, DisGeNET, and GeneCards databases. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses characterized core target functions. Hub targets of DLT against AS were identified through machine learning algorithms. Combined single-cell and bulk transcriptomic profiling revealed AS-associated immune pathway modulation. Molecular docking and dynamics simulations validated ligand-target interactions. Cellular thermal shift assay (CETSA) combined with enzyme-linked immunosorbent assay (ELISA) in human umbilical vein endothelial cells (HUVECs) provided preliminary evidence for target engagement. A total of 138 bioactive DLT components were identified, with six high-degree constituents: quercetin, β-sitosterol, kaempferol, luteolin, naringenin, and formononetin. A total of 230 overlapping targets linked DLT to AS. GO analysis indicated DLT modulates stress response, metabolism, and signal transduction. KEGG analysis highlighted potential anti-AS effects via AGE-RAGE and IL-17 pathways. Machine learning prioritized HSF1, HAS2, PTGS1, NFATC1, and CD40LG as candidate targets. Correlation analysis revealed that HAS2 expression was significantly associated with inflammatory markers (IL6: r = 0.58, P < 0.001; TNF: r = 0.52, P = 0.002). Molecular docking identified HAS2-β-sitosterol (- 10.5 kcal/mol) and PTGS1-quercetin (- 8.8 kcal/mol) as top-binding pairs. CETSA validated β-sitosterol-HAS2 and quercetin-PTGS1 target engagement. This integrative approach proposes HAS2 as a novel candidate target mediating the anti-AS effects of β-sitosterol, providing new molecular hypotheses and a potential target landscape for future experimental validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.